Welcome to Gene Therapy: Repairing the Genetic Code
Imagine having an instruction manual with a single torn or misprinted page that causes a machine to malfunction. In biology, our DNA is that instruction manual, and a single faulty gene can lead to a serious inherited condition. But what if we could deliver a fresh, correct copy of that page directly into the cells that need it? That is the core idea behind gene therapy.
In this chapter from Unit A2 5 (Genetics, Stem Cell Research and Cloning), we will explore how scientists use gene technology to treat genetic disorders, the biological tools used to deliver genes into human cells, and the crucial scientific and ethical challenges involved.
1. Understanding Gene Therapy
What is Gene Therapy?
Gene therapy is a therapeutic technique where a functional, normal copy of a gene is inserted into specific target cells of an individual who has a genetic disorder. This disorder is typically caused by a mutated, non-functional, or missing gene. Delivering the normal gene restores the cell's ability to produce the required functional protein.
Analogy Time: Think of a cell as a factory kitchen. If the master recipe card for a vital enzyme is smudged and unreadable (a mutated gene), the chefs cannot cook the meal (the functional protein). Gene therapy delivers a crisp, working copy of that recipe card straight to the kitchen counter.
Target Conditions: Monogenic Disorders
Gene therapy is primarily aimed at monogenic disorders (conditions caused by a mutation in a single gene), rather than polygenic conditions (caused by multiple interacting genes). The CCEA specification focuses on two classic examples:
1. Cystic Fibrosis (CF):
• The Cause: Mutations in the CFTR gene (cystic fibrosis transmembrane conductance regulator).
• The Therapy: Introducing a normal, functional copy of the CFTR gene into the airway epithelial cells of the lungs so they can correctly transport chloride ions and prevent thick, sticky mucus build-up.
2. Severe Combined Immunodeficiency (SCID):
• The Cause: A deficiency in the ADA gene (adenosine deaminase), which prevents white blood cells from maturing and leaves the patient with virtually no immune defence.
• The Therapy: Inserting a functional ADA gene into hematopoietic (bone marrow) stem cells so the body can produce healthy immune cells.
Key Takeaway: Gene therapy treats monogenic disorders by inserting a healthy copy of a gene into affected cells to restore production of a vital functional protein.
2. Somatic vs Germ-Line Gene Therapy
There are two fundamental types of gene therapy, distinguished by the types of cells targeted and whether the changes can be passed to future generations.
A. Somatic Cell Gene Therapy (SCGT)
• Target Cells: Non-reproductive body cells (somatic cells), such as lung epithelial cells, muscle cells, or bone marrow stem cells.
• Heritability: Not heritable. The inserted genes will never enter sperm or egg cells, meaning the genetic changes cannot be passed on to the patient's children.
• Duration of Effect: Often transient (temporary). Because somatic cells have a finite lifespan, divide, and naturally die off, treatments usually need to be repeated periodically.
• UK Legal Status: Legally and ethically approved in the UK for clinical treatment under strict regulatory control.
B. Germ-Line Gene Therapy (GLGT)
• Target Cells: Reproductive cells (gametes: sperm or ova) or early-stage zygotes/embryonic stem cells.
• Heritability: Heritable. The introduced gene integrates into every single cell of the developing individual and is passed down to all future generations.
• UK Legal Status: Prohibited and illegal in humans under UK law.
Why is Germ-Line Gene Therapy Prohibited?
While the prospect of permanently eliminating a genetic disease from a family bloodline sounds appealing, it introduces serious ethical and scientific concerns:
1. Lack of Informed Consent: Unborn future generations cannot consent to permanent genetic alterations.
2. Unpredictable Long-Term Risks: Unintended genetic mutations or side effects would permanently alter the human gene pool.
3. Social & Ethical Concerns: Fears of "designer babies", eugenics, and genetic discrimination.
Memory Trick: Remember Somatic = Stays with the patient. Germ-line = Goes to the next Generation.
Key Takeaway: Somatic gene therapy affects only body cells and cannot be inherited (legal in the UK). Germ-line therapy modifies gametes or embryos, creating permanent heritable changes (illegal in the UK).
3. Vectors: Delivering the Gene
Naked DNA cannot easily enter human target cells on its own because cell membranes act as barriers, and free DNA is rapidly broken down. Scientists use transport vehicles called vectors to deliver the functional gene into host cells.
1. Viral Vectors
Viruses naturally infect human cells to inject their genetic material. In gene therapy, scientists harness this ability by using genetically modified, harmless viruses where pathogenic replication genes have been removed or inactivated.
• Retroviruses / Lentiviruses:
These vectors insert their genetic material directly into the host cell's nuclear DNA. Because the new gene becomes part of the host chromosomes, it is copied when the cell divides by mitosis, offering longer-term expression in dividing cells.
• Adenoviruses:
These vectors deliver the therapeutic DNA directly into the cell nucleus without integrating it into the host's chromosomes (the gene remains episomal). Because the gene is not integrated, it is not replicated during mitosis, resulting in transient (short-lived) expression.
2. Non-Viral Vectors
• Liposomes (Lipid Nanoparticles): Artificial microscopic spheres made of a phospholipid bilayer encapsulating the functional DNA. Because lipids blend easily with the cell membrane, liposomes can fuse with the target cell membrane or be taken up by endocytosis to release DNA inside.
• Direct Injection / Electroporation: Physical introduction of naked plasmid DNA into target tissue, sometimes using brief electrical pulses (electroporation) to temporarily open pores in cell membranes.
Key Takeaway: Vectors act like delivery vans. Viral vectors use disarmed viruses to insert DNA, while non-viral vectors (like liposomes) use lipid bubbles to cross cell membranes.
4. Limitations, Complications, and Risks
Gene therapy holds immense promise, but several significant biological hurdles explain why it is not yet a routine cure for every condition.
1. Immune and Inflammatory Response
The patient's immune system may recognise the viral vector or the newly produced protein as a foreign antigen. This can trigger a severe inflammatory reaction, destroying the newly treated cells before they can provide therapeutic benefit.
2. Insertional Mutagenesis and Oncogenesis (Cancer Risk)
When integrating viral vectors (like retroviruses) insert therapeutic genes into the host DNA, they do so somewhat randomly. If the gene accidentally inserts into the middle of a vital tumour suppressor gene (inactivating it) or lands next to an oncogene (activating it), it can trigger uncontrolled cell division, leading to leukaemia or cancer.
3. Transient Expression & The Need for Repeated Treatments
Why do patients need repeat treatments? Examiners look for this two-part explanation:
• Cell Turnover: Somatic target cells (such as epithelial cells lining the lungs in cystic fibrosis) have a finite lifespan and are continuously shed and replaced.
• Lack of Integration: If non-integrating vectors (like adenoviruses or liposomes) are used, the foreign DNA is not copied during mitosis and is lost as new cells form.
4. Vector Inefficiency and Targeting Difficulties
Delivering vectors to enough cells in vivo is difficult. For instance, in Cystic Fibrosis, vectors must pass through thick, dehydrated layers of respiratory mucus to reach the underlying airway epithelial cells, resulting in low delivery efficiency.
Key Takeaway: Gene therapy challenges include immune rejection of vectors, cancer risks from random DNA integration (insertional mutagenesis), physical barriers like mucus, and short-term gene expression requiring repeat treatments.
5. Common Exam Pitfalls & Examiner Tips
• Pitfall 1: Claiming somatic therapy stops inheritance.
Exam Tip: Always state that somatic cell modifications are restricted solely to the patient's differentiated body tissues and are NOT passed on to offspring.
• Pitfall 2: Writing "the medicine wears off".
Exam Tip: Never use vague phrasing. Explain the biological reason: somatic cells have limited lifespans, undergo natural cell turnover/replacement, and non-integrated genes are not replicated during mitosis.
• Pitfall 3: Calling viral vectors "infections".
Exam Tip: Always mention that the virus is genetically modified, disarmed, or inactivated so that it cannot replicate or cause disease.
• Pitfall 4: Mixing up UK legal statuses.
Exam Tip: Remember that Somatic Cell Gene Therapy is legal and clinically used in the UK, whereas Germ-Line Gene Therapy is illegal and prohibited in humans.
Quick Revision Checklist
Can you answer these key revision questions?
1. What is the difference in heritability between somatic and germ-line gene therapy?
2. Which gene and target tissue are involved in gene therapy for Cystic Fibrosis?
3. Why are retroviruses more likely to cause insertional mutagenesis than adenoviruses?
4. Why does gene therapy for CF airway cells need to be administered repeatedly?
5. State two ethical reasons why germ-line gene therapy is banned in the UK.